Seraseq Genomic DNA Tumor Mutational Burden (TMB)In immuno oncology, the goal is to enable a patients immune system to locate and eliminate cancerous cells. The immune system may normally protect against cancer except when cancers manage to evade it since immunocompromised individuals have a higher likelihood of developing cancer. Checkpoint inhibitors, which have recently improved the prognosis for a significant number of cancer patients, work by blocking inhibitory molecules such as PD L1 and CTLA